DEF: ORIC Pharmaceuticals Sets 2026 Annual Meeting Date

ORIC Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 18, 2026, to be held virtually, with key proposals including director elections, auditor ratification, and equity plan approval.

Summary

• ORIC Pharmaceuticals, Inc. is holding its 2026 Annual Meeting of Stockholders on June 18, 2026, at 8:00 a.m. Pacific Time, conducted virtually via live audio webcast.
• The meeting agenda includes the election of two Class III directors, ratification of KPMG LLP as the independent registered public accounting firm for fiscal year 2026, approval of the amended and restated 2020 Equity Incentive Plan, and advisory votes on executive compensation and its frequency.
• Stockholders of record as of April 20, 2026, are entitled to vote.
• Proxy materials are being made available on or about April 28, 2026.
• The company's board of directors recommends voting 'FOR' all proposals, including the election of directors, ratification of the auditor, approval of the equity plan, and advisory approval of executive compensation, recommending an annual frequency for future advisory votes on executive compensation.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it outlines standard corporate governance procedures and proposals for an annual meeting, with a focus on maintaining competitive compensation structures while addressing shareholder concerns about dilution.

Positives

• The company is holding its annual meeting to engage with stockholders and address key governance and compensation matters.
• The virtual format for the annual meeting enhances accessibility for all stockholders.
• The board of directors is actively seeking stockholder input on executive compensation and its frequency.
• The proposed amendments to the 2020 Equity Incentive Plan aim to balance talent attraction/retention with responsible equity usage and reduced dilution.

Negatives

• The filing does not contain financial performance results, as it is a proxy statement for an upcoming meeting.
• The proposed amendments to the equity plan reduce the annual share reserve increase from 5% to 4%, which could be viewed negatively by employees seeking more equity.

Risks

• If the Amended 2020 Equity Incentive Plan is not approved, the company may be unable to make sufficient long-term equity incentive awards, potentially impacting recruitment and retention in a competitive market.
• The classification of the board of directors may have the effect of delaying or preventing changes in control of the company.

Future Outlook

The company is seeking stockholder approval for amendments to its 2020 Equity Incentive Plan, which it believes are necessary to continue attracting, motivating, and retaining service providers through equity awards. If approved, the company anticipates not needing to request additional shares for the plan until its 2030 annual meeting, based on current projections.

Management Comments

• "We believe this format affords the same rights and opportunities to participate in the Annual Meeting to all stockholders irrespective of location."
• "Whether or not you attend the Annual Meeting, it is important that your shares be represented and voted at the Annual Meeting. Therefore, we urge you to promptly vote and submit your proxy via the Internet, by phone, or by signing, dating and returning the enclosed proxy card in the enclosed envelope."
• "The board of directors, its compensation committee, and management believe that grants of equity awards, including, but not limited to, incentive stock options, to employees and other service providers motivate high levels of performance to achieve our goals, provide an effective means for recognizing contributions that promote our success, and promote the closer alignment of the interests of our service providers with those of our stockholders by providing the perspective of an owner with an equity stake in the Company."
• "The compensation committee believes that maintaining an appropriately sized pool of shares under the 2020 Plan is critical to attract, retain and engage the high-caliber employees and other service providers needed to execute our strategy, especially in key scientific and clinical roles."
• "In our industry, there is significant competition for experienced and educated individuals with the skills necessary to execute our strategy and advance our business. Our success depends on such key employees. Equity compensation is a core component of our employment value proposition and aligns employees with the long-term interests of our stockholders."
• "The board of directors recommends that future non-binding advisory votes on the compensation of our named executive officers be held every year in line with market best practices."

Industry Context

StockSavvy.ai notes that ORIC Pharmaceuticals, as a biotechnology company, relies heavily on equity compensation to attract and retain specialized talent in a highly competitive market. The proposed amendments to their equity incentive plan reflect common industry practices and governance trends, balancing the need for incentives with stockholder concerns about dilution.

Comparison to Industry Standards

• ORIC's historical 3-year average burn rate of 4.77% is noted as falling below the peer 25th percentile and the ISS VABR benchmark of 4.2%, indicating responsible equity spend practices compared to industry peers.
• The proposed elimination of the ability for the plan administrator to implement an 'Exchange Program' (e.g., repricing underwater awards) aligns with current governance best practices and addresses common investor concerns in the biotechnology sector.
• The recommendation to hold advisory votes on executive compensation annually is in line with market best practices for publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Will vote on director elections, auditor ratification, executive compensation, and the equity incentive plan. The equity plan amendments aim to balance dilution concerns with the need for competitive incentives.
• Employees: Will be eligible for equity awards under the amended 2020 Equity Incentive Plan, which aims to attract and retain talent.
• Directors: Nominees are up for election; current directors' compensation is being adjusted to be more competitive.
• Executive Officers: Have an interest in the election of directors, executive compensation approval, and the equity incentive plan, as they are eligible to receive awards.

Next Steps

• Stockholders to vote on the proposals at the 2026 Annual Meeting of Stockholders.
• If approved, the Amended 2020 Equity Incentive Plan will replace the current plan.
• Final voting results will be published in a Form 8-K filing within four business days after the Annual Meeting.

Key Dates

Recommendation

This filing is a proxy statement for an upcoming annual meeting and does not contain financial performance results or significant strategic updates that would warrant a buy or sell recommendation. It outlines standard corporate governance proposals and compensation-related matters. A 'hold' recommendation is appropriate as investors await future operational and financial performance updates.

Keywords

Proxy Statement, Annual Meeting, Stockholder Vote, Director Election, Executive Compensation, Equity Incentive Plan, Independent Auditor, Corporate Governance, ORIC Pharmaceuticals